UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center

在当前的精密医学时代，实验室研究是癌症临床试验不可或缺的组成部分。 在将治疗与特定患者联系起来的最强大的技术中，有一种是询问 核酸(DNAseq和/或RNAseq)，现在最典型的是使用大规模并行 测序(MPS)。RNAseq现在为查询肿瘤基因组提供了一种极其强大的方法， 其中基因表达谱在提供预后信息、预测信息、 以及关于肿瘤微环境的关键信息，包括免疫的定量测量 渗透。此外，基于dna的方法在检测体细胞方面也可以提供临床信息。 序列改变(突变)、结构变异(融合)、正常DNA序列丢失(缺失)或 序列增益(放大)。或者，测序分析可以将非癌细胞的DNA定向到 解决其他问题，包括识别家族易感性和药物基因分型 代谢酶具有重要的治疗作用。 通过这个项目，北卡罗来纳大学/UTHSC单位团队将在 从拨款的第一天起就以合规的方式。作为人类RNA生产的世界领先者- 基于来自冷冻和FFPE的癌症数据，包括RNA测序和靶向RNA定量， 基于RNA的检测是在合规的环境中提供的。我们对公共事务也非常有经验，而且 复杂的、基于DNA的分析，并提供这些。该提案的目标1和2涉及提供FDA- 以及符合CAP的机制，用于从样本中进行RNA和DNA测序的高样本吞吐量 由多机构合作团体试验提供。RNA测序将以三种格式提供，RNA- SEQ、纳米串和Q-RT-PCR，以实现全面覆盖和廉价的靶向RNA 侧写。DNA测序将为MPS的整个外显子组和靶向捕获以及 用纳米线对DNA进行定量测量。第三个目标是开发和提供数据共享格式和 用于适当传播基于临床试验序列的患者信息的基础设施，这是 我们需要的是这个大数据时代。

In the current era of Precision Medicine, laboratory studies are an integral component of cancer clinical trials. Amongst the most powerful techniques connecting therapies to specific patients are assays that interrogate nucleic acids (DNAseq and/or RNAseq), which are now most typically done using massively parallel sequencing (MPS). RNAseq now offers an extremely powerful approach for querying the tumor genome, where gene expression profiles have proven value in providing prognostic information, predictive information, and also critical information on the tumor microenvironment including quantitative measures of immune infiltrations. In addition, DNA based approaches can also be clinically informative in detecting somatic sequence alterations (mutations), structural variations (fusions), loss of normal DNA sequences (deletions), or sequence gains (amplifications). Alternatively, sequencing assays can target DNA from noncancerous cells to address additional questions including identification of familial predisposition, and genotyping of drug metabolizing enzymes of therapeutic importance. Through this Project, the UNC / UTHSC UNITS team will provide high volume clinical grade sequencing in a regulatory compliant manner from day one of the grant. As a world leader in the production of human RNA- based cancer data, from both frozen and FFPE, including RNA sequencing and targeted RNA quantification, RNA-based assays are offered within a compliant setting. We are also highly experienced with common, and complex, DNA-based assays and offer these as well. Aims 1 and 2 of this proposal involve providing an FDA- and CAP- compliant mechanism for high sample throughput for RNA- and DNA-sequencing from samples provided from multi-institutional cooperative group trials. RNA sequencing will be offered in 3 formats, RNA- Seq, NanoString, and Q-rt-PCR, to allow both comprehensive coverage and inexpensive targeted RNA profiling. DNA sequencing will be offered for both whole exome and targeted capture by MPS, as well as quantitative DNA measures by NanoString. The third aim is to develop and provide data sharing formats and an infrastructure for the proper dissemination of clinical trial sequence-based patient information, which is needed is this era of Big Data.